NADMED secures funding to bring NAD measurement tech to the US

Finnish firm claims its take a look at is the primary to measure ranges of all types of NAD and glutathione immediately from blood samples.

Finland-based biotech NADMED has secured €3.5 million in a Collection A funding spherical to advance its proprietary expertise that measures nicotinamide adenine dinucleotide (NAD) ranges within the physique. The corporate intends to make use of the funding to deliver its blood take a look at for the longevity-linked molecules to the US and different worldwide markets.

NADs are important molecules current in each cell of the human physique, enjoying a important function in vitality manufacturing, mobile restore and development. Together with glutathiones, a key antioxidant, NAD ranges are essential to sustaining mobile well being. Imbalances in NAD and glutathione ranges have been linked to quite a few age-related illnesses, together with metabolic issues, neurodegenerative circumstances, cardiovascular illnesses and muscle atrophy, and correct measurement of NAD and glutathione ranges will help perceive and deal with these circumstances.

NADMED claims its expertise, developed within the lab of Professor Anu Suomalainen Wartiovaara on the College of Helsinki, is the primary to measure all types of NAD immediately from contemporary blood samples. In contrast with mass spectrometry, which has limitations by way of value, throughput and the kind of NAD kinds it will probably measure, NADMED says its methodology is each sooner and less expensive, whereas sustaining the identical excessive degree of accuracy. The system additionally measures completely different types of glutathione from the identical pattern.

NADMED’s deliberate growth into the US market comes at a time when metabolism and metabolic well being are attracting important consideration.

“Within the coming years, metabolism would be the hottest matter in medication and biology, particularly when utilized to personalised well being and illness understanding,” mentioned Jari Närhi, CEO of NADMED. “On this dawning age of metabolism, NAD would be the new DNA. This funding will allow us to deliver new capabilities to diagnostics, remedy monitoring, personalised medication, and development of metabolic science for the good thing about mankind.”

NADMED’s take a look at kits are supposed to be used by medical laboratories, pharmaceutical firms and researchers engaged in drug improvement and medical research. One of many potential advantages of the expertise highlighted by the corporate is the power to supply extra personalised therapy choices. NAD ranges could be elevated with B3 vitamin supplementation, which has proven constructive results in managing circumstances akin to Parkinson’s illness, glaucoma and mitochondrial myopathy. Nonetheless, the response to NAD-boosting remedies varies between people. NADMED’s strategy permits for extra exact monitoring of those ranges, serving to clinicians tailor therapy to the affected person’s particular metabolic wants.

The brand new funding was led by Nordic Science Investments (NSI), with extra assist from prior backers akin to Voima Ventures, College of Helsinki Funds, non-public European traders and Enterprise Finland. The funding will assist NADMED additional develop its product and lengthen its attain in key markets. The corporate already serves clients in 27 nations, together with medical laboratories, universities, analysis establishments and pharmaceutical firms.